These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18417061)

  • 21. Evacetrapib.
    Nicholls SJ
    Curr Cardiol Rep; 2012 Jun; 14(3):245-50. PubMed ID: 22362199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
    Ghosh RK; Ghosh SM
    Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
    Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
    N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDL- cholesterol: a nut too hard to crack?
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352
    [No Abstract]   [Full Text] [Related]  

  • 26. JTT-705: is there still future for a CETP inhibitor after torcetrapib?
    Rennings AJ; Stalenhoef A
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches to atherosclerotic cardiovascular disease. the potentialities of torcetrapib.
    Pérez-Castrillon JL; Dueñas-Laita A
    Recent Pat Cardiovasc Drug Discov; 2006 Jan; 1(1):109-14. PubMed ID: 18221079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?
    Ahmed MH
    Diabetes Technol Ther; 2008 Aug; 10(4):328-9. PubMed ID: 18715207
    [No Abstract]   [Full Text] [Related]  

  • 29. The therapeutic potential of CETP inhibitors: a patent review.
    Wang X; Li W; Hao L; Xie H; Hao C; Liu C; Li W; Xiong X; Zhao D
    Expert Opin Ther Pat; 2018 Apr; 28(4):331-340. PubMed ID: 29424255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
    Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH
    Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 39. The end of the road for CETP inhibitors after torcetrapib?
    Joy T; Hegele RA
    Curr Opin Cardiol; 2009 Jul; 24(4):364-71. PubMed ID: 19522058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissociating HDL cholesterol from cardiovascular risk.
    Hausenloy DJ; Opie L; Yellon DM
    Lancet; 2010 Jul; 376(9738):305-6. PubMed ID: 20655104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.